Vizora日本語

Kobayashi PharmaceuticalKOBAYASHI PHARMACEUTICAL CO.,LTD.4967東証プライム化学FY ending Dec 2025, consolidated, J-GAAP

Kobayashi Pharmaceutical FY ending Dec 2025 results

About 71% of Kobayashi Pharmaceutical's sales come from Domestic Business, with International Business and Other making up much of the rest.

Out of every ¥100 of sales, about ¥9 is left as operating profit.

Revenue changed +0.1% from the prior year, operating profit -40.0%.

Revenue and profit pattern

Revenue up, profit downRevenue grew faster

Revenue +0.1% · profit -40.0%, calculated from disclosed figures.

What changed from last year

FY ending Dec 2024 → FY ending Dec 2025

Revenue
+0.1%¥165.6B → ¥165.7B
Gross profit
-3.3%¥87.6B → ¥84.7B
Operating income
-40.0%¥24.9B → ¥14.9B
Net income attributable to owners
-63.7%¥10.1B → ¥3.66B
Operating cash flow
+127.5%¥11.2B → ¥25.6B
Free cash flow
Back to profit-¥15.4B → ¥11.6B

Where the money goes

FY ending Dec 2024 → FY ending Dec 2025

Where ¥100 of sales goes

For every ¥100 Kobayashi Pharmaceutical sells, how much goes where, and how much is kept.

FY ending Dec 2025
Cost of sales
¥49
SG&A
¥42
Operating profit
¥9
Net profit kept
¥2

Annual margin trends

Gross margin51.1%
FY ending Dec 2020: 56.6%56.6%FY ending Dec 2021: 57.2%57.2%FY ending Dec 2022: 55.5%55.5%FY ending Dec 2023: 55.6%55.6%FY ending Dec 2024: 52.9%52.9%FY ending Dec 2025: 51.1%51.1%FY20FY21FY22FY23FY24FY25
Operating margin9.0%
FY ending Dec 2020: 17.2%17.2%FY ending Dec 2021: 16.8%16.8%FY ending Dec 2022: 16.0%16.0%FY ending Dec 2023: 14.9%14.9%FY ending Dec 2024: 15.0%15.0%FY ending Dec 2025: 9.0%9.0%FY20FY21FY22FY23FY24FY25
Net margin2.2%
FY ending Dec 2020: 12.8%12.8%FY ending Dec 2021: 12.7%12.7%FY ending Dec 2022: 12.0%12.0%FY ending Dec 2023: 11.7%11.7%FY ending Dec 2024: 6.1%6.1%FY ending Dec 2025: 2.2%2.2%FY20FY21FY22FY23FY24FY25

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Dec 2025

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (6)

  • EDINET (FSA Japan)

    有価証券報告書－第108期(2025/01/01－2025/12/31)

    ID S100XSXS2026-03-25Open

  • EDINET (FSA Japan)

    有価証券報告書－第107期(2024/01/01－2024/12/31)

    ID S100VIKQ2025-03-28Open

  • EDINET (FSA Japan)

    有価証券報告書－第106期(2023/01/01－2023/12/31)

    ID S100T3KX2024-03-28Open

  • EDINET (FSA Japan)

    有価証券報告書－第105期(2022/01/01－2022/12/31)

    ID S100QGIS2023-03-30Open

  • EDINET (FSA Japan)

    有価証券報告書－第104期(令和3年1月1日－令和3年12月31日)

    ID S100NR6F2022-03-30Open

  • EDINET (FSA Japan)

    有価証券報告書－第103期(令和2年1月1日－令和2年12月31日)

    ID S100L0OB2021-03-26Open

Extracted from XBRL: 52 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image